Holen Sie sich die Stockscreener-App
0.6375
10.87%
0.0625
Handel nachbörslich:
.63
-0.0075
-1.18%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt LXRX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$0.575
Offen:
$0.5788
24-Stunden-Volumen:
12.92M
Relative Volume:
0.91
Marktkapitalisierung:
$221.49M
Einnahmen:
$1.21M
Nettoeinkommen (Verlust:
$-177.12M
KGV:
-0.7969
EPS:
-0.8
Netto-Cashflow:
$-162.37M
1W Leistung:
+24.49%
1M Leistung:
+75.52%
6M Leistung:
-67.14%
1J Leistung:
-62.72%
1-Tages-Spanne:
$0.577
$0.6445
1-Wochen-Bereich:
$0.48
$0.6445
52-Wochen-Spanne:
$0.2836
$2.45
Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile
Firmenname
Lexicon Pharmaceuticals Inc
Sektor
Branche
Telefon
(281) 863-3000
Adresse
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
Vergleichen Sie LXRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LXRX
Lexicon Pharmaceuticals Inc
|
0.6375 | 221.49M | 1.21M | -177.12M | -162.37M | -0.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
490.47 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
585.49 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
599.87 | 36.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
236.75 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
252.77 | 25.74B | 3.81B | -644.79M | -669.77M | -6.24 |
Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-05 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-06-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-04-30 | Eingeleitet | Leerink Partners | Outperform |
| 2023-03-07 | Eingeleitet | Jefferies | Hold |
| 2022-08-12 | Eingeleitet | Piper Sandler | Overweight |
| 2021-01-29 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-01-29 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-12-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-11-18 | Hochstufung | Gabelli & Co | Hold → Buy |
| 2019-12-11 | Herabstufung | Gabelli & Co | Buy → Hold |
| 2019-11-08 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-09-11 | Hochstufung | Gabelli & Co | Hold → Buy |
| 2019-07-29 | Herabstufung | Stifel | Buy → Hold |
| 2019-03-25 | Hochstufung | Gabelli & Co | Sell → Hold |
| 2018-07-31 | Bestätigt | Stifel | Buy |
| 2018-02-23 | Herabstufung | Needham | Buy → Hold |
| 2018-02-14 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2017-03-01 | Bestätigt | H.C. Wainwright | Buy |
| 2017-03-01 | Bestätigt | Wedbush | Outperform |
| 2016-10-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-08-05 | Bestätigt | Wedbush | Outperform |
| 2016-08-02 | Eingeleitet | Citigroup | Buy |
| 2016-03-02 | Bestätigt | Wedbush | Outperform |
| 2015-11-09 | Bestätigt | Wedbush | Outperform |
| 2015-09-28 | Hochstufung | Gabelli & Co | Sell → Hold |
| 2015-09-18 | Herabstufung | Gabelli & Co | Hold → Sell |
| 2015-08-10 | Herabstufung | JP Morgan | Overweight → Neutral |
Alle ansehen
Lexicon Pharmaceuticals Inc Aktie (LXRX) Neueste Nachrichten
Form ARS LEXICON PHARMACEUTICALS, For: Dec 31 - StreetInsider
Lexicon Pharmaceuticals at Needham Conference: Strategic Shift in Focus By Investing.com - Investing.com Canada
Novo Nordisk inks licensing pact with Lexicon for obesity candidate - MSN
LXRX Stock Moves Up 30% in a Week: What is Driving This Rally? - MSN
Lexicon Pharmaceuticals to present at Healthcare Conference By Investing.com - Investing.com South Africa
Lexicon Pharmaceuticals to present at Healthcare Conference - Investing.com
Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference - The Manila Times
Lexicon Pharma (LXRX) to Present at the 24th Annual Needham Virtual Healthcare Conference - StreetInsider
Social Buzz: Wallstreetbets Stocks Mixed Premarket Tuesday; Tesla to Advance, Lexicon Pharmaceuticals to Decline - MarketScreener
Lexicon Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:LXRX) - MarketBeat
Novo Nordisk gains rights to novel small molecule inhibitor - European Pharmaceutical Review
Houston-area company inks massive $1B deal for weight-loss drug - Chron
Novo Nordisk licenses Lexicon’s preclinical obesity drug in $1B deal - BioWorld MedTech
US Stocks Likely To Open Lower After 3-Day Fall: 'Equity Drawdown Probability Hasn't Peaked Yet,' Says Goldman Sachs Analyst - Benzinga
The Woodlands-based company strikes obesity-drug license deal worth up to $1B - KHOU
Biotech Firms Celebrate Gains With Promising Trials And Partnerships - Finimize
Lexicon's Drug Discovery Engine Validated By Novo's $1 Billion Obesity Drug Deal (Upgrade) - Seeking Alpha
Novo Nordisk Inks Its Second Big Obesity Deal In A Week — And It's Not For A GLP-1 - Investor's Business Daily
What 6 Analyst Ratings Have To Say About Lexicon Pharmaceuticals - Fidelity
Novo Nordisk Lands Lexicon Pharma Obesity Drug With Potential to Pair With GLP-1s - MedCity News
Lexicon Pharmaceuticals, Novo Nordisk strike obesity-drug license deal worth up to $1B - The Business Journals
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Novo Nordisk strikes $1bn deal for Lexicon’s oral obesity drug - Yahoo Finance
Lexicon (LXRX) Secures $1 Billion Deal with Novo Nordisk for Obe - GuruFocus
Novo Adds Lexicon’s Novel Obesity Drug To Deal Flurry - insights.citeline.com
Novo Nordisk to license obesity drug from Lexicon in up to $1 billion deal - Reuters
Lexicon Pharmaceuticals: Strategic Partnerships and Pipeline Advancements Drive Buy Rating - TipRanks
Lexicon Pharma soars as it licenses LX9851 to Novo Nordisk - The Pharma Letter
Nasdaq Down 100 Points; Federal Reserve's Favorite Inflation Gauge Increases More Than Expected - Benzinga
Lexicon inks $1 billion deal with Novo Nordisk for obesity drug By Investing.com - Investing.com South Africa
Lexicon stock rises on Novo Nordisk licensing deal (LXRX) - Seeking Alpha
Sector Update: Health Care Stocks Steady Premarket Friday - MarketScreener
Lexicon Pharmaceuticals (LXRX) Soars 95% on Novo Nordisk Licensi - GuruFocus.com
Penny Stock Lexicon Pharmaceuticals Surges On Obesity Pact Worth $1 Billion With Novo Nordisk - Benzinga
Novo Nordisk in licensing deal with Lexiconcould pay up to $1 billion - MarketScreener
Lexicon inks $1 billion deal with Novo Nordisk for obesity drug - Investing.com India
Lexicon Pharmaceuticals Enters License Agreement With Novo Nordisk for Obesity Drug; Shares Jump - MarketScreener
Lexicon Pharmaceuticals Announces Exclusive License Agreement With Novo Nordisk For LX9851 - Marketscreener.com
Lexicon Pharma (LXRX) Announces Exclusive License Agreement with Novo Nordisk for LX9851 - StreetInsider
Lexicon's Game-Changing Obesity Drug Catches Novo Nordisk's Eye in Billion-Dollar Deal - Stock Titan
Chronic Neuropathic Pain Market to Reach New Heights in Growth - openPR
Finanzdaten der Lexicon Pharmaceuticals Inc-Aktie (LXRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Lexicon Pharmaceuticals Inc-Aktie (LXRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Swain Judith L | Director |
Apr 28 '24 |
Option Exercise |
0.00 |
8,032 |
0 |
48,364 |
| SOBECKI CHRISTOPHER J | Director |
Apr 28 '24 |
Option Exercise |
0.00 |
8,032 |
0 |
167,055 |
| LEFKOWITZ ROBERT J MD | Director |
Apr 28 '24 |
Option Exercise |
0.00 |
8,032 |
0 |
48,364 |
| DEBBANE RAYMOND | Director |
Apr 28 '24 |
Option Exercise |
0.00 |
8,032 |
0 |
1,348,879 |
| BARKER SAM L | Director |
Apr 28 '24 |
Option Exercise |
0.00 |
8,032 |
0 |
87,649 |
| Amouyal Philippe | Director |
Apr 28 '24 |
Option Exercise |
0.00 |
8,032 |
0 |
248,364 |
1.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):